TORONTO and HAIFA, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the second quarter ended June 30, 2025 (“Q2”), and provide a corporate update on its recent activities and upcoming milestones.
The Company’s full set of unaudited condensed interim consolidated financial statements for the six months ended June 30, 2025, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.